This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Relevance to Dermatology

Charles Camisa, MD

Arch Dermatol. 1989;125(3):407-412.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Somatostatin, release inhibitor hormone or factor, was first isolated from hypothalamic extracts by Guillemin and Gerich¹ in 1972. As is illustrated in Altman and associates' work,² published in this issue of the ARCHIVES, this hormone and its analogues may be useful in treating a variety of diseases caused by the excess of certain hormones and mediators of inflammation. The 14-amino acid peptide was subsequently identified in pancreas (D cells of the islets of Langerhans), stomach, small intestine, and throughout the central and peripheral nervous systems. The amino acid sequence of somatostatin and its synthesis in the laboratory were quickly followed by many pharmacologic and physiologic studies, which revealed that somatostatin has many actions in addition to inhibiting the secretion of growth hormone (Table 1).³

The original authors recognized that somatostatin might have clinical applications in the management of acromegaly and juvenile diabetes. However, several undesirable characteristics . . . [Full Text PDF of this Article]

Author Affiliations
From the Section of Clinical Dermatology, Department of Dermatology, Cleveland Clinic Foundation.

Footnotes
Accepted for publication Aug 30, 1988.

Reprint requests to Department of Dermatology A61, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44106 (Dr Camisa).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?